A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone

Trial Profile

A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Finerenone (Primary) ; Eplerenone
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms ARTS-HF Japan
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Apr 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 09 Nov 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top